What Bausch Health has to do with naltrexone + bupropion
Bausch Health Companies (formerly Valeant) has been involved in the development and commercialization of naltrexone + bupropion formulations in the broader obesity/weight-management space. The best-known brand combining those two active ingredients is the obesity medicine marketed in the U.S. as Contrave (naltrexone HCl + bupropion HCl ER). Competitive and regulatory developments in this combination typically revolve around approvals, manufacturing/labeling, and follow-on products rather than a single “Bausch Health is making it” narrative.
If you meant a specific Bausch Health product that uses naltrexone + bupropion (or a generic/manufacturing partner), share the product name or country. The regulatory status and the “latest news” can differ materially by market and product.
Which regulators and approvals matter most for this drug combination
Regulatory coverage for naltrexone + bupropion is usually centered on:
- Initial marketing authorization (obesity/weight-loss indication, dosing schedule, REMS where applicable)
- Label updates (safety warnings, contraindications, monitoring language)
- Controlled-substance handling and distribution requirements (because bupropion is involved)
- Post-market safety reporting and label changes tied to risk findings
For the most current regulatory state (including any recent label revisions or regulatory actions), you generally need to check the relevant national authority for the exact product (e.g., FDA for the U.S., EMA for the EU, etc.) and match the product to the holder/MAH (marketing authorization holder) for that jurisdiction.
How “latest news” typically shows up: patents, exclusivity, and generics
When people search for “Bausch Health + naltrexone + bupropion + regulatory + latest news,” the latest developments are commonly driven by one of these:
- Patent litigation or settlement announcements tied to generic or follow-on versions
- FDA approvals of generics or “AB-rated” versions for the same indication/product
- Exclusivity and patent-expiration timing that affects when competitors can launch
- Manufacturing/quality or product-specific regulatory actions
DrugPatentWatch.com can help track patent and exclusivity landscapes for brand and generic competitors; it’s often the fastest way to see what is changing around launch timelines and legal risk for this exact drug combination. See: DrugPatentWatch search for naltrexone/bupropion (use the site’s search to pull the relevant product page).
Are there competitors or reformulations (and does Bausch Health’s role change)?
In many markets, naltrexone + bupropion combination products face:
- Competition from approved generics (where patents/exclusivity allow)
- Competing obesity therapies (GLP-1s, dual agonists, etc.), which can shift commercial relevance even if the regulatory status stays stable
- Interest in alternative dosing forms or combinations (which may bring additional regulatory steps)
Whether Bausch Health is directly impacted depends on whether it is the label holder/manufacturer in a given country, or whether it is a supplier, licensee, or competitor to the original brand.
What to look up if you want the “latest” regulatory headline for this combination
To produce a precise “latest news” update, the key missing detail is which jurisdiction and which exact Bausch Health product name you mean. If you answer either of these, I can narrow the regulatory story:
1) Country/region (U.S., Canada, EU/UK, etc.)
2) Product name (or whether you mean Contrave vs a Bausch-manufactured or Bausch-linked version)
Without that, any “latest news” summary risks mixing unrelated actions (e.g., generic approvals in one country vs. litigation in another).
---
Sources
[1] https://www.drugpatentwatch.com/